Retinoblastoma surgery: Difference between revisions
Simrat Sarai (talk | contribs) No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Retinoblastoma}} | {{Retinoblastoma}} | ||
{{CMG}}{{AE}}{{Simrat}} | |||
==Overview== | ==Overview== | ||
Enucleation remains the definitive treatment of intraocular retinoblastoma, particularly in the majority of patients who present with unilateral disease. | Enucleation remains the definitive treatment of intraocular retinoblastoma, particularly in the majority of patients who present with unilateral disease. | ||
==Surgery== | ==Surgery== | ||
Enucleation is indicated for: | |||
*Group E tumor, based on International classification for Retinoblastoma. Group E tumors are large tumors (>50 percent of globe volume) with limited to no visual potential, painful eyes, and/or tumors that extend into the optic nerve. | |||
* | *Advanced group D tumors may require enucleation, particularly in the setting of unilateral disease. | ||
* | *Enucleation is also the preferred treatment in eyes that have poor visual potential and have failed previous "globe-conserving" approaches. | ||
* | *Enucleation is often performed if the eye has any one of the following: | ||
**Secondary glaucoma | |||
**Poor view to the fundus with presumed active tumor | |||
**Anterior chamber invasion | |||
Potential complications of enucleation include scleral perforation with seeding of tumor cells into the orbit. | |||
Adjuvant systemic chemotherapy or brachytherapy may be considered in patients with high-risk features to prevent metastatic disease (eg, ciliary body, iris, massive scleral, or choroidal infiltration, and invasion of the optic nerve posterior to the lamina cribrosa). Adjuvant chemotherapy may reduce the development of contralateral or intracranial tumors (PNET) in children with a germline mutation [114]. When there is a positive optic nerve margin or extrascleral/trans-scleral extension, external beam radiotherapy should be considered.<ref name="pmid12096963">{{cite journal| author=Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J et al.| title=Postenucleation adjuvant therapy in high-risk retinoblastoma. | journal=Arch Ophthalmol | year= 2002 | volume= 120 | issue= 7 | pages= 923-31 | pmid=12096963 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12096963 }} </ref> Although somewhat controversial, adjuvant chemotherapy may reduce the development of contralateral or intracranial tumors (PNET) in the child with a germline mutation. <ref name="pmid22084213">{{cite journal| author=Kaliki S, Shields CL, Shah SU, Eagle RC, Shields JA, Leahey A| title=Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma. | journal=Arch Ophthalmol | year= 2011 | volume= 129 | issue= 11 | pages= 1422-7 | pmid=22084213 | doi=10.1001/archophthalmol.2011.289 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22084213 }} </ref> An orbital implant (typically hydroxyapatite or porous polyethylene) is placed at the time of enucleation. After Approximately after six weeks when the conjunctiva has healed, a prosthesis can be fitted by an ocularist. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 01:04, 14 October 2015
|
Retinoblastoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Retinoblastoma surgery On the Web |
|
American Roentgen Ray Society Images of Retinoblastoma surgery |
|
Risk calculators and risk factors for Retinoblastoma surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Enucleation remains the definitive treatment of intraocular retinoblastoma, particularly in the majority of patients who present with unilateral disease.
Surgery
Enucleation is indicated for:
- Group E tumor, based on International classification for Retinoblastoma. Group E tumors are large tumors (>50 percent of globe volume) with limited to no visual potential, painful eyes, and/or tumors that extend into the optic nerve.
- Advanced group D tumors may require enucleation, particularly in the setting of unilateral disease.
- Enucleation is also the preferred treatment in eyes that have poor visual potential and have failed previous "globe-conserving" approaches.
- Enucleation is often performed if the eye has any one of the following:
- Secondary glaucoma
- Poor view to the fundus with presumed active tumor
- Anterior chamber invasion
Potential complications of enucleation include scleral perforation with seeding of tumor cells into the orbit. Adjuvant systemic chemotherapy or brachytherapy may be considered in patients with high-risk features to prevent metastatic disease (eg, ciliary body, iris, massive scleral, or choroidal infiltration, and invasion of the optic nerve posterior to the lamina cribrosa). Adjuvant chemotherapy may reduce the development of contralateral or intracranial tumors (PNET) in children with a germline mutation [114]. When there is a positive optic nerve margin or extrascleral/trans-scleral extension, external beam radiotherapy should be considered.[1] Although somewhat controversial, adjuvant chemotherapy may reduce the development of contralateral or intracranial tumors (PNET) in the child with a germline mutation. [2] An orbital implant (typically hydroxyapatite or porous polyethylene) is placed at the time of enucleation. After Approximately after six weeks when the conjunctiva has healed, a prosthesis can be fitted by an ocularist.
References
- ↑ Honavar SG, Singh AD, Shields CL, Meadows AT, Demirci H, Cater J; et al. (2002). "Postenucleation adjuvant therapy in high-risk retinoblastoma". Arch Ophthalmol. 120 (7): 923–31. PMID 12096963.
- ↑ Kaliki S, Shields CL, Shah SU, Eagle RC, Shields JA, Leahey A (2011). "Postenucleation adjuvant chemotherapy with vincristine, etoposide, and carboplatin for the treatment of high-risk retinoblastoma". Arch Ophthalmol. 129 (11): 1422–7. doi:10.1001/archophthalmol.2011.289. PMID 22084213.